CD63作为卵巢癌患者的一种潜在生物标志物。

CD63 as a potential biomarker for patients with ovarian cancer.

作者信息

Nakamura Keiichiro, Ida Naoyuki, Hirasawa Akira, Okamoto Kazuhiro, Vu Thuy Ha, Hai Ly Dao Thi, Masuyama Hisashi

机构信息

Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho kitaku, Okayama 700-8558, Japan.

出版信息

Eur J Obstet Gynecol Reprod Biol. 2025 Mar;306:87-93. doi: 10.1016/j.ejogrb.2025.01.011. Epub 2025 Jan 7.

DOI:10.1016/j.ejogrb.2025.01.011

PMID:39799740

Abstract

INTRODUCTION

Exosomes play an important role in regulating physiological processes and mediating the systemic dissemination of various types of cancer. We investigated the association of exosomal tetraspanins CD9, CD63, and CD81 in patients with ovarian cancer (OC).

MATERIAL AND METHODS

We measured the plasma tetraspanins CD9, CD63, and CD81 by enzyme-linked immunosorbent assay in 91 patients who underwent treatment for OC between April 2018 and March 2024. Additionally, we analyzed clinical pathologic factors, chemotherapy response, and prognosis.

RESULTS

In terms of stages, CD63 expression was significantly higher in patients with stage IV compared to those with stage I OC (p = 0.003). In terms of histological type, CD63 expression was significantly higher in high-grade serous carcinoma (HGSC) than in clear cell carcinoma (CCC) with OC (p = 0.009). Furthermore, CD63 levels were significantly higher in advanced-stage, HGSC than in patients with early-stage, non-HGSC and early-stage, HGSC OC (p = 0.045 and p = 0.002, respectively). In the Neoadjuvant chemotherapy (NAC) of 12 patients with OC assessed as having either a partial response (PR) or complete response (CR), CD63 was significantly decreased (p = 0.043), whereas perforin was significantly increased (p = 0.001). In the NAC of 16 patients with OC, CD63 of the response rate to chemotherapy tended to differ between the progressive disease (PD) and PR/CR groups (p = 0.056). A moderate inverse correlation was observed between CD63 and perforin levels (R = 0.638, R = 0.428, p = 0.008).

CONCLUSIONS

CD63 could be a potential biomarker for all types of OC patients.

摘要

引言

外泌体在调节生理过程和介导各类癌症的全身扩散中发挥着重要作用。我们研究了卵巢癌（OC）患者中外泌体四跨膜蛋白CD9、CD63和CD81之间的关联。

材料与方法

我们采用酶联免疫吸附测定法，对2018年4月至2024年3月期间接受OC治疗的91例患者的血浆四跨膜蛋白CD9、CD63和CD81进行了检测。此外，我们分析了临床病理因素、化疗反应和预后情况。

结果

在分期方面，与I期OC患者相比，IV期患者的CD63表达显著更高（p = 0.003）。在组织学类型方面，高级别浆液性癌（HGSC）中CD63的表达显著高于OC的透明细胞癌（CCC）（p = 0.009）。此外，晚期HGSC患者的CD63水平显著高于早期非HGSC和早期HGSC OC患者（分别为p = 0.045和p = 0.002）。在对12例评估为部分缓解（PR）或完全缓解（CR）的OC患者进行的新辅助化疗（NAC）中，CD63显著降低（p = 0.043），而穿孔素显著升高（p = 0.001）。在16例OC患者的NAC中，化疗反应率的CD63在疾病进展（PD）组和PR/CR组之间存在差异趋势（p = 0.056）。观察到CD63与穿孔素水平之间存在中度负相关（R = 0.638，R = 0.428，p = 0.008）。